Livedoid vasculitis
Livedoid vasculitis ni ugonjwa sugu wa ngozi unaoonekana zaidi kwa wanawake wachanga hadi wa makamo. Kifupi kimoja kinachotumika kuelezea sifa zake ni "Painful purpuric ulcers with reticular pattern of the lower extremities" (PURPLE). Inahusishwa na idadi ya magonjwa, ikiwa ni pamoja na shinikizo la damu la muda mrefu la venous na varicosities.
☆ Katika matokeo ya 2022 ya Stiftung Warentest kutoka Ujerumani, kuridhika kwa watumiaji na ModelDerm kulikuwa chini kidogo kuliko na mashauriano ya matibabu ya simu yanayolipishwa.
Inaweza kuambatana na maumivu.
References
Livedoid vasculopathy ni ugonjwa adimu wa ngozi unaodhihirishwa na vidonda vya maumivu vinavyoendelea kurudi kwenye miguu ya chini.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy ni hali adimu ya ngozi ambayo husababisha vidonda vya mara kwa mara kwenye miguu ya chini, na kuacha makovu ya rangi inayojulikana kama atrophie blanche. Ingawa sababu halisi bado haijafahamika, inaaminika kuwa kuongezeka kwa damu kuganda (hypercoagulability) ndio sababu kuu, huku uvimbe ukichukua nafasi ya pili. Mambo yanayochangia kuganda ni pamoja na kama ifuatavyo - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. Katika biopsies, hali hiyo inaonyesha vifungo vya damu ndani ya vyombo, unene wa kuta za chombo, na makovu. Matibabu huhusisha mbinu nyingi zinazolenga kuzuia kuganda kwa damu kwa kutumia dawa kama vile dawa za kupunguza damu, dawa za kupunguza damu, na tiba ya fibrinolytic. Dawa mbalimbali zinaweza kutumika kwa hali hii ya ngozi - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy ni hali adimu ambapo vidonda hutokea kwenye miguu yote miwili. Uundaji wa vipande vya damu katika mishipa midogo ya damu hufikiriwa kusababishwa na kuongezeka kwa kuganda na kuvunjika kwa damu, pamoja na uharibifu wa safu ya chombo. Huwapata zaidi wanawake, hasa kati ya umri wa miaka 15 na 50. Kuacha kuvuta sigara, kutunza majeraha, na kutumia dawa kama vile dawa za kupunguza damu na antiplatelet kumekuwa na ufanisi.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.
